When COVID-19 began to spread uncontrollably, numbers of confirmed cases initially grew most quickly in developed economies across China, Europe and then the US.
As technological advances unlock a more nuanced understanding of disease – and exciting opportunities for personalised medicine – some cancers are now being redefined as rare diseases.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
